-
6 Minute Walk Distance To Measure Functional Capacity Early after Liver Transplantation, The
-
6-Month Universal CMV Prophylaxis and Neutropenia in Kidney Transplant Patients Induced with Alemtuzumab: A Single Center Retrospective Study
-
699 Living Donor Kidney Transplants Using Alemtuzumab Pretreatment and Tacrolimus Monotherapy: 10 Year Experience
-
7 Years Experience with Multiplex TMA-NAT-Based Assay for HIV and HCV Screening among Organ and Tissue Donors – Definitive Report
-
Abnormal Distribution of B-Cell Populations Associated with Impaired Regulatory Functions in Chronic Antibody Mediated Rejection
-
ABO Antibody Removal of Plasmapheresis (PP) with Intravenous Immunoglobulin (IVIG) before ABO-Incompatible (ABOI) Kidney Transplantation
-
ABO Incompatible Kidney Transplantation Using Subcutaneous Alemtuzumab for Induction and No Post Transplant Plasmapheresis
-
ABO-Incompatible Kidney Transplantation Protects the Graft from Natural Antibodies Induced Damage and Prevents Immune Responses to Donor HLA and Kidney Associated Self Antigens Leading to Long Term Rejection Free Survival
-
Abrogation of Chronic Rejection Involves Down Regulation of mTOR/Rac1 Pathway
-
Absence of the MicroRNA miR-182 in CD4+T Cells Prolongs Allograft Survival
2013 American Transplant Congress
May 18-22, 2013 in Seattle, Washington